Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Sagar Lonial,Rafat Abonour,Keli Song,Deborah Berg,Vivek Roy,Omar Nadeem,Christine K Ward,Yuhong Zhang,Jeremy T Larsen,Cara A Rosenbaum,Ralph V Boccia,Meera Mohan,Igor Proscurshim,Habte Yimer,Bo H Chao ,Saulius Girnius ,Moshe Levy ,Akira Nakamura ,Stefano Tarantolo ,Allison Berger ,Santosh Kumar

doi:10.1182/blood-2021-148385

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Sagar Lonial, Rafat Abonour + Show 19 more

Open Access

https://doi.org/10.1182/blood-2021-148385

Copy DOI

Journal: Blood

Publication Date: Nov 5, 2021

Affiliation: Emory University, Indiana University – Purdue University Indianapolis, Takeda (United States), Mayo Clinic, Dana-Farber Cancer Institute, Mayo Clinic Hospital, Cornell University, New York Hospital Queens, NewYork–Presbyterian Hospital, Center for Cancer and Blood Disorders, Medical College of Wisconsin, Texas Oncology, TriHealth, Baylor University Medical Center, Nebraska Cancer Specialists

#Speakers Bureau #Research Funding + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

More From: Blood

Paper Title

Journal

Date

Author

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.